Today: 3 June 2026
IonQ Revenue Surge Puts Quantum Stocks Back in Focus, but QTUM ETF Shows Why Hype May Be Ahead
23 March 2026
2 mins read

IonQ Revenue Surge Puts Quantum Stocks Back in Focus, but QTUM ETF Shows Why Hype May Be Ahead

NEW YORK, March 23, 2026, 12:10 PM EDT

  • IonQ climbed roughly 4% by midday Monday, while QTUM advanced over 2%. Rigetti and D-Wave joined the move higher.
  • IonQ’s 2025 revenue landed at $130 million, dwarfing D-Wave’s $24.6 million and Rigetti’s $7.1 million.
  • QTUM’s assets have topped $3.5 billion, yet the fund’s exposure to four U.S. pure-play quantum stocks comes in at only 2.92%.

Quantum-computing stocks saw gains Monday—IonQ advanced roughly 4%, while Rigetti Computing and D-Wave Quantum also traded higher. By midday in New York, the Defiance Quantum ETF had added over 2%. Still, recent earnings reports suggest that significant revenue remains largely limited to a handful of players.

The split’s getting attention as investor flows chase the quantum theme ahead of mainstream takeup. Defiance reported QTUM crossed $3.5 billion in assets last month. Over in public markets, IonQ became the first quantum pure-play to hit $100 million in annual GAAP revenue—a milestone both D-Wave and Rigetti missed by a wide margin, booking $24.6 million and $7.1 million respectively for 2025.

IonQ stands out as the most straightforward growth play here. Revenue in 2025 soared 202% to $130 million, with commercial clients making up over 60% of that figure. Looking ahead, the company projects $225 million to $245 million in 2026 sales. “Strategic and financial inflection point”—that’s how CEO Niccolo de Masi described 2025. IonQ Investors

Still, IonQ’s story is all about the long runway. The company logged a net loss of $510.4 million for 2025, and as of Monday, its $18.3 billion valuation came in at over 140 times last year’s revenue. That’s before anyone knows if management’s $1.8 billion SkyWater agreement will actually give it the manufacturing muscle they’re aiming for.

D-Wave’s numbers are running hot. The company reported 2025 revenue up 179% to $24.6 million. By Feb. 25, first-quarter-to-date 2026 bookings were already past $32.8 million. CEO Alan Baratz put it plainly: D-Wave is heading into 2026 with “exceptional momentum.” D-Wave

Rigetti posted just $7.1 million in revenue for 2025. Still, Chief Executive Subodh Kulkarni pointed to growing interest from governments and research outfits—highlighting an $8.4 million order from India’s C-DAC for a 108-qubit system. For reference, a qubit is the basic unit of quantum information.

QTUM’s structure sheds some light on its wider appeal, outpacing the interest typically seen in single-stock bets. As of March 23, Nvidia and Alphabet each made up roughly 1.19% of the portfolio. IonQ, D-Wave, Rigetti, and Quantum Computing Inc—taken together—represented only 2.92% of assets.

QTUM isn’t strictly a quantum play—it’s more of a catch-all covering semis, software, and a spread of advanced computing names. Back in February, Defiance reported the ETF had topped $3.5 billion in assets. As of Feb. 28, its website showed a 49.26% one-year market-price return.

Government backing is propping up the sector, too. Last week, Britain pledged as much as 2 billion pounds for quantum technologies, with procurement programs aimed at pushing commercial-scale systems out of labs and into real-world domestic use.

Public markets keep betting on potential rather than profits. Steve Sosnick at Interactive Brokers summed it up: it’s about “the right price to pay for a piece of the future.” Defiance CIO Sylvia Jablonski points to the appeal—”science fiction has moved” into the business world. That disconnect is still the sector’s main play. Reuters

Stock Market Today

  • AstraZeneca Shares Dip 10.6% in 3 Months Despite Pipeline Growth Prospects
    June 3, 2026, 3:57 PM EDT. AstraZeneca (LSE:AZN) shares have fallen 10.6% over the past three months amid cooling momentum, although the stock remains up 24.8% over the past year. The company, valued at about £204.9 billion with annual revenues of $60.4 billion, shows a 44.6% intrinsic value discount against its current price of £132.10. Analysts estimate a fair value of £163.06, indicating the stock could be about 19% undervalued based on a 7.2% discount rate. AstraZeneca's late-stage pipeline, particularly in oncology and rare diseases, could generate over $10 billion in peak revenue, driving future growth. However, risks include government price controls and biosimilar competition. The current price-to-earnings ratio of 26.5x exceeds peers but remains below a fair ratio of 35.3x, suggesting potential valuation risks if sentiment declines further.

Latest articles

Oklo Stock Is Getting Hit. The Insider-Sale Filing Traders Are Watching

Oklo Stock Is Getting Hit. The Insider-Sale Filing Traders Are Watching

3 June 2026
Oklo plunged about 10% to $65.89 after a June 2 SEC filing revealed 200,000 Class A shares sold June 1 under a pre-arranged insider-trading plan tied to CEO Jacob DeWitte, triggering a sharper drop than peers as investors reacted to the insider-sale disclosure despite ongoing U.S. nuclear fuel-supply momentum and recent government selection for advanced reactor fuel talks.
Apple Shares Slip Ahead of Key AI Event

Apple Shares Slip Ahead of Key AI Event

3 June 2026
Apple shares slid 1.8% to $309.67 as investors grew cautious ahead of the June 8 WWDC, where Apple is expected to reveal AI advancements; UBS sees limited upside from the event, while Morgan Stanley and BofA are more bullish, making the keynote a key test for Apple’s valuation and future iPhone demand.
T1 Energy Stock Gets a $32 Million Battery Test as AI Power Demand Builds

T1 Energy Stock Gets a $32 Million Battery Test as AI Power Demand Builds

3 June 2026
T1 Energy shares held nearly flat after announcing a $32 million deal to acquire KORE Power, expanding into battery storage and data-center infrastructure; Northland initiated coverage with an Outperform rating and $16 price target but highlighted funding and ramp-up risks, as T1 aims for positive EBITDA in 2026 and $15–20 million EBITDA contribution in 2027, pending deal closure and KORE shareholder approval.
Grab Shares Slide After Q1 Beat, Investors Eye Market Headwinds

Grab Shares Slide After Q1 Beat, Investors Eye Market Headwinds

3 June 2026
Grab shares slid 5.7% to $3.395 in heavy Nasdaq trading, underperforming after strong Q1 results with revenue up 24% and adjusted EBITDA up 46%, as investors worried about rising fuel costs, Indonesia’s planned commission cap, and broader market weakness driven by Middle East tensions and higher oil prices.
Ondas Stock Falls After Final Q4 Earnings Reverse Profit Signal, 2026 Revenue Target Jumps to $375M
Previous Story

Ondas Stock Falls After Final Q4 Earnings Reverse Profit Signal, 2026 Revenue Target Jumps to $375M

US Stock Market Today: Dow, S&P 500, Nasdaq Surge as Oil Tumbles on Iran Reprieve
Next Story

US Stock Market Today: Dow, S&P 500, Nasdaq Surge as Oil Tumbles on Iran Reprieve

Go toTop